CD4+ and CD8+ T Cells Can Act Separately in Tumour Rejection after Immunization with Murine Pneumotropic Virus Chimeric Her2/neu Virus-Like Particles

被引:12
作者
Andreasson, Kalle [1 ]
Eriksson, Mathilda [1 ]
Tegerstedt, Karin [1 ]
Ramqvist, Torbjorn [1 ]
Dalianis, Tina [1 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
来源
PLOS ONE | 2010年 / 5卷 / 07期
基金
英国医学研究理事会;
关键词
NK CELLS; ANTITUMOR IMMUNITY; IFN-GAMMA; DNA VACCINATION; HEPARAN-SULFATE; DENDRITIC CELLS; POLYOMA-VIRUS; ANTIGEN; MICE; EXPRESSION;
D O I
10.1371/journal.pone.0011580
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Immunization with murine pneumotropic virus virus-like particles carrying Her2/neu (Her2MPtVLPs) prevents tumour outgrowth in mice when given prophylactically, and therapeutically if combined with the adjuvant CpG. We investigated which components of the immune system are involved in tumour rejection, and whether long-term immunological memory can be obtained. Methodology and Results: During the effector phase in BALB/c mice, only depletion of CD4(+) and CD8(+) in combination, with or without NK cells, completely abrogated tumour protection. Depletion of single CD4(+), CD8(+) or NK cell populations only had minor effects. During the immunization/induction phase, combined depletion of CD4(+) and CD8(+) cells abolished protection, while depletion of each individual subset had no or negligible effect. When tumour rejection was studied in knock-out mice with a C57B1/6 background, protection was lost in CD4(-/-) CD8(-/-) and CD4(-/-), but not in CD8(-/-) mice. In contrast, when normal C57B1/6 mice were depleted of different cell types, protection was lost irrespective of whether only CD4(+), only CD8(+), or CD4(+) and CD8(+) cells in combination were eradicated. No anti-Her2/neu antibodies were detected but a Her2/neu-specific IFN gamma response was seen. Studies of long-term memory showed that BALB/c mice could be protected against tumour development when immunized together with CpG as long as ten weeks before challenge. Conclusion: Her2MPtVLP immunization is efficient in stimulating several compartments of the immune system, and induces an efficient immune response including long-term memory. In addition, when depleting mice of isolated cellular compartments, tumour protection is not as efficiently abolished as when depleting several immune compartments together.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors
    Andreasson, Kalle
    Tegerstedt, Karin
    Eriksson, Mathilda
    Curcio, Claudia
    Cavallo, Federica
    Forni, Guido
    Dalianis, Tina
    Ramqvist, Torbjoern
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) : 150 - 156
  • [2] THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN
    BARGMANN, CI
    HUNG, MC
    WEINBERG, RA
    [J]. NATURE, 1986, 319 (6050) : 226 - 230
  • [3] Polyomavirus EGFP-pseudocapsids:: Analysis of model particles for introduction of proteins and peptides into mammalian cells
    Boura, E
    Liebl, D
    Spísek, R
    Fric, J
    Marek, M
    Stokrová, J
    Holán, V
    Forstová, J
    [J]. FEBS LETTERS, 2005, 579 (29): : 6549 - 6558
  • [4] The CC chemokine CKβ-11/MIP-3β/ELC/exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
    Braun, SE
    Chen, KY
    Foster, RG
    Kim, CH
    Hromas, R
    Kaplan, MH
    Broxmeyer, HE
    Cornetta, K
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (08) : 4025 - 4031
  • [5] Bronte V, 2000, CANCER RES, V60, P253
  • [6] CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination
    Cheng, WF
    Hung, CF
    Lin, KY
    Ling, M
    Juang, J
    He, L
    Lin, CT
    Wu, TC
    [J]. GENE THERAPY, 2003, 10 (16) : 1311 - 1320
  • [7] Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
    Disis, ML
    Knutson, KL
    Schiffman, K
    Rinn, K
    McNeel, DG
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (03) : 245 - 252
  • [8] POLYOMA-VIRUS RECOGNIZES SPECIFIC SIALYLOLIGOSACCHARIDE RECEPTORS ON HOST-CELLS
    FRIED, H
    CAHAN, LD
    PAULSON, JC
    [J]. VIROLOGY, 1981, 109 (01) : 188 - 192
  • [9] Human papillomavirus infection requires cell surface heparan sulfate
    Giroglou, T
    Florin, L
    Schäfer, F
    Streeck, RE
    Sapp, M
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (03) : 1565 - 1570
  • [10] STUDIES IN ANTIBODY RESPONSE OF MICE TO TUMOUR INOCULATION
    GORER, PA
    [J]. BRITISH JOURNAL OF CANCER, 1950, 4 (04) : 372 - 379